But more important than modifying risk factors, the GLP-1 RAs provide patients with type 2 diabetes on average a 14% relative risk reduction for major cardiovascular events, including: Cardiovascular death Heart attack Stroke Three GLP-1 RAs have been indicated by the FDA to reduce heart disease risk in people with type 2 diabetes who have or are at high risk for blockages of arteries of the heart, brain, and legs, also known as atherosclerotic cardiovascular disease (ASCVD): Dulaglutide, which is branded as Trulicity and is currently the only GLP-1 RA approved for cardiovascular disease risk reduction in patients with or without established ASCVD Liraglutide, which is branded as Victoza and was the first GLP-1 RA to show efficacy for heart benefits in a clinical trial Semaglutide, which has been increasingly prescribed off-label as a weight-loss medication under the brand name Ozempic Whereas we are still exploring the biological mechanisms of how GLP-1 Ras benefit the heart, the body of evidence we have at present is already revolutionizing the care of patients with type 2 diabetes
.png)
Stop using retinol and AHAs 3-5 days before treatment
The patient was taking a glucagon-like peptide-1 (GLP-1) receptor agonist
Average weight loss at 3 months ranges from 5 to 12 pounds, depending on your starting dose, adherence, diet, and activity level
Viola: [00:29:21] Sure
